Aratana Therapeutics Inc. (NASDAQ:PETX) – Stock analysts at Lake Street Capital issued their Q2 2017 earnings per share (EPS) estimates for Aratana Therapeutics in a report released on Monday. Lake Street Capital analyst B. Jackson expects that the brokerage will earn ($0.33) per share for the quarter. Lake Street Capital has a “Buy” rating and a $15.00 price objective on the stock. Lake Street Capital also issued estimates for Aratana Therapeutics’ Q3 2017 earnings at ($0.30) EPS and Q4 2017 earnings at ($0.27) EPS.

PETX has been the topic of a number of other research reports. Zacks Investment Research upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating and set a $9.00 price target on the stock in a research report on Wednesday. Credit Suisse Group AG reiterated a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a research report on Wednesday, August 10th. Barclays PLC reduced their price target on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. William Blair reiterated an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Jefferies Group started coverage on Aratana Therapeutics in a research report on Friday, August 19th. They issued a “buy” rating and a $13.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Aratana Therapeutics currently has a consensus rating of “Buy” and an average price target of $11.00.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) traded down 0.313% during trading on Tuesday, reaching $7.955. The company’s stock had a trading volume of 103,845 shares. The firm has a 50 day moving average price of $8.85 and a 200-day moving average price of $7.73. The stock’s market cap is $279.16 million. Aratana Therapeutics has a 52-week low of $2.56 and a 52-week high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.10. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. During the same period last year, the business earned ($1.58) EPS.

In other news, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the transaction, the insider now directly owns 115,494 shares of the company’s stock, valued at $1,154,940. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction on Friday, September 9th. The stock was sold at an average price of $9.25, for a total value of $277,500.00. Following the completion of the sale, the insider now owns 72,424 shares in the company, valued at approximately $669,922. The disclosure for this sale can be found here. Company insiders own 6.70% of the company’s stock.

Several large investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in shares of Aratana Therapeutics during the third quarter worth about $11,259,000. General American Investors Co. Inc. acquired a new stake in shares of Aratana Therapeutics during the second quarter worth about $2,604,000. First Light Asset Management LLC increased its stake in shares of Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock worth $4,329,000 after buying an additional 236,915 shares during the period. Vanguard Group Inc. increased its stake in shares of Aratana Therapeutics by 20.4% in the second quarter. Vanguard Group Inc. now owns 1,270,655 shares of the biopharmaceutical company’s stock worth $8,031,000 after buying an additional 214,900 shares during the period. Finally, Iguana Healthcare Management LLC acquired a new stake in shares of Aratana Therapeutics during the first quarter worth about $1,070,000. Institutional investors own 88.77% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.